Angioedema is a medical condition characterized by localized inflammatory swelling of the dermis, mucosa or submucosa tissue. It usually affects the extremities of limbs, face, genitals and intestinal tract. The condition is caused due to increased permeability of capillaries and small veins leading to fluid retention in surrounding tissues. Common symptoms include swelling of the hands, feet, legs, face, gastrointestinal tract and genitals. Angioedema can occur both hereditary as well as acquired forms. The global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The angioedema treatment market is driven by the increased prevalence of hereditary as well as acquired angioedema disease. As per estimates provided by Hereditary Angioedema Association, approximately 1 in 10,000 to 1 in 50,000 people suffer from hereditary angioedema globally. Moreover, according to a study published by NCBI in 2014, the prevalence of acquired angioedema was estimated to be approximately 1.1 cases per 100,000 population per year in the United States. The rising disease incidences have resulted in growing adoption of treatment medications such as C1-esterase inhibitor replacements and bradykinin receptor blockers for angioedema management. Furthermore, advancements in diagnosis and treatment regimens over the past few years have improved patient outcomes, thereby favoring market growth during the forecast period.
SWOT Analysis
Strength: Angioedema treatment market has promising growth owing torising prevalence of hereditary angioedema (HAE) across the globe. Advancement in treatment options such as approved therapies like C1-esterase inhibitor replacement therapy and bradykinin B2 receptor antagonistshave significantly improved patient outcomes. Major players are focused on developing novel therapies for effective treatment of angioedema attack as well as prophylaxis.
Weakness: High treatment cost associated with approved therapies hampers patient adherence. Biosimilar competitionrestrains pricing flexibility of innovator drugs. Dependence on reimbursement policies in certain regions poses weakness.
Opportunity: Significant unmet needs remain for expanding treatment window and reducing injection frequency. Emerging oral drugs and pipeline products offer opportunities. Growing health insurance penetration and out of pocket spending capacity in developing nations supports market growth.
Threats: Patent expiries of flagship drugs present generic competition threats. Stringent regulations for biosimilar approval delays market entry of lower cost drugs. Reimbursement barriers in price sensitive markets pose threats.
Key Takeaways
The global Angioedema Treatment Market is expected to witness high growth during 2023-2030 period owing to rising HAE prevalence and improving diagnosis rates globally. The North American region is currently dominating the market due to developed healthcare infrastructure and high adoption of expensive therapies.
Regional analysis: North America presently holds over 35% revenue share driven by the US healthcare system spending capability. Europe follows due to favourable reimbursement scenario and awareness campaigns. Asia Pacific represents fastest growth fueled byIndia, China and other Southeast Asian developing countries. Rising medical tourism coupled with government initiatives supports market expansion in Asia Pacific region.
Key players: Key players operating in the Angioedema Treatment market are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd.
Major players focus on developing oral prophylaxis drugs and expanding geographical footprint through licensing agreements. Partnerships with regional pharma companies helps key players to accelerate market penetration in high growth regions. Launch of affordable biosimilars by key generics makersprovide cost effective treatment options for patients.
